<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165525</url>
  </required_header>
  <id_info>
    <org_study_id>DD01112019</org_study_id>
    <nct_id>NCT04165525</nct_id>
  </id_info>
  <brief_title>ConMed HelixAR™ ElectroSurgical Generator With Argon Beam Coagulation Technology Study</brief_title>
  <acronym>CHEST</acronym>
  <official_title>ConMed HelixAR™ ElectroSurgical Generator With Argon Beam Coagulation Technology (CHEST) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SurgiQuest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SurgiQuest, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY TO EVALUATE DEVICE EFFICACY BETWEEN THE HELIXAR&#xD;
      ELECTROSURGICAL GENERATOR (HEG) VS. CONVENTIONAL ELECTROSURGICAL COAGULATION (CEC) FOR&#xD;
      CUTTING AND/OR COAGULATION OF TISSUE DURING MASTECTOMY PROCEDURES&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate device efficacy between the HelixAR&#xD;
      Electrosurgical Generator (HEG) and Conventional Electrosurgical Coagulation (CEC) Systems&#xD;
      for cutting and/or coagulation of tissue during mastectomy procedures and reconstructive&#xD;
      surgery.&#xD;
&#xD;
      The study is designed and powered to demonstrate the superiority of the HEG to CEC in&#xD;
      relation to a key efficacy measure: post-mastectomy procedure time to hemostasis. Secondary&#xD;
      outcome measures include: infection, drain duration, total drain output, blood loss, and&#xD;
      device related adverse events. These outcomes will be evaluated in a controlled population&#xD;
      undergoing mastectomy procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Perspective, randomized, concurrently controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time measured from post-mastectomy to hemostasis for each operated breast.</measure>
    <time_frame>Inter-operative</time_frame>
    <description>time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>drain output</measure>
    <time_frame>up to two weeks post surgery</time_frame>
    <description>ml</description>
  </secondary_outcome>
  <other_outcome>
    <measure>infection rate</measure>
    <time_frame>two months from procedure</time_frame>
    <description>comparison between arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Mastectomy; Lymphedema</condition>
  <arm_group>
    <arm_group_label>HelixAR Electrosurgical Generator (HEG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Argon gas and high frequency electrical current ablation device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Electrosurgical Coagulation (CEC) Systems</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Bovie electrosugical device without argon gas</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.</description>
    <arm_group_label>Conventional Electrosurgical Coagulation (CEC) Systems</arm_group_label>
    <arm_group_label>HelixAR Electrosurgical Generator (HEG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 80 years of age;&#xD;
&#xD;
          2. Capable and willing to give informed consent;&#xD;
&#xD;
          3. Acceptable candidate for a unilateral or bilateral mastectomy and reconstruction. All&#xD;
             subjects enrolled and consented will undergo mastectomy with a breast reconstruction&#xD;
             procedure, if it is in the subject's best interest.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Advanced refusal of blood transfusion, if necessary;&#xD;
&#xD;
          2. Active systemic or cutaneous infection or inflammation;&#xD;
&#xD;
          3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;&#xD;
&#xD;
          4. Uncontrolled diabetes mellitus&#xD;
&#xD;
          5. Known, significant history of bleeding diathesis, or coagulopathy, or Von Willebrand's&#xD;
             disease or current platelet count &lt; 100,000 cells/mm3, or baseline INR ≥1.8, or&#xD;
             fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24&#xD;
             hours);&#xD;
&#xD;
          6. Severe co-existing morbidities having a life expectancy of less than 30 days;&#xD;
&#xD;
          7. Currently involved in any other investigational clinical studies that could influence&#xD;
             outcomes;&#xD;
&#xD;
          8. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than&#xD;
             30%;&#xD;
&#xD;
          9. Renal insufficiency (serum creatinine of &gt; 2.5 mg/dl);&#xD;
&#xD;
         10. Females who are pregnant, planning to become pregnant within 3 months of the&#xD;
             procedure, or lactating;&#xD;
&#xD;
         11. Patients who have had previous partial mastectomies with scar tissue affecting the&#xD;
             area to be resected.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey A Carter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>cynthia C Harris, BS</last_name>
    <phone>8326776747</phone>
    <email>cindy@clinregconsult.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael A Daniel, BS, MS,MB</last_name>
    <phone>4154070223</phone>
    <email>madaniel@clinregconsult.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baylor St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Menegaz</last_name>
      <email>Brian.Menegaz@bcm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://seer.cancer.gov/statfacts/html/breast.html</url>
    <description>Breast cancer statstical facts</description>
  </link>
  <reference>
    <citation>McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ. Effects of age on the detection and management of breast cancer. Cancers (Basel). 2015 May 22;7(2):908-29. doi: 10.3390/cancers7020815. Review.</citation>
    <PMID>26010605</PMID>
  </reference>
  <reference>
    <citation>Steiner, C.A.; Weiss, A.J.; Barrett, M.L.; Fingar, K.R.; Davis, P.H (2016).</citation>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>comparison of ablation devices</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

